Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus bivalent vaccine (types 16, 18) (Xiamen University)
- Development stage
- Unknown
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The human papillomavirus bivalent vaccine (types 16, 18) is a recombinant prophylactic vaccine developed by Xiamen University and Xiamen Innovax Biotech. Marketed as Xinkenin in China and Cecolin internationally, it is the first HPV vaccine produced using an Escherichia coli expression system, distinguishing it from yeast- or insect cell-based alternatives. The vaccine consists of L1 virus-like particles (VLPs) of HPV types 16 and 18, which are the primary drivers of cervical cancer. It is indicated for the prevention of HPV 16/18-related infections and associated diseases, including cervical, vulvar, and vaginal cancers, as well as intraepithelial neoplasias (CIN, VIN, VaIN). It was approved by China's National Medical Products Administration (NMPA) in 2019 for use in females aged 9 to 45 years.
- Brand names
- XinkeninCecolin
- Other names
- Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)HPV 16/18 (E. coli) vaccine
02
Targets
HPV16 (Human papillomavirus type 16)HPV18 L1
Beyond the preview
Go deeper on human papillomavirus bivalent vaccine (types 16, 18) (Xiamen University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus bivalent vaccine (types 16, 18) (Xiamen University).